<DOC>
	<DOCNO>NCT03072147</DOCNO>
	<brief_summary>The purpose study evaluate teriparatide ( TP ) chondroregenerative therapy human knee osteoarthritis ( OA ) . The central hypothesis test TP support structural modification joint improve biomarker , functional patient-reported measure knee OA .</brief_summary>
	<brief_title>Teriparatide Chondroregenerative Therapy OA</brief_title>
	<detailed_description>This prospective , randomize , placebo control , double blind , crossover study . The investigator identify , recruit enroll 80 subject symptomatic , unilateral medial compartment knee OA . Enrolled subject randomize equal TP ( FDA approve form , Forteo ) placebo arm 40 subject ( include allowance 25 % dropout rate replacement ) . All subject treat 24 week , follow additional 24 week assess durability observe effect . The trial incorporate crossover design , base interim analysis 24 week outcome data every subject complete 24 week treatment period . If positive effect structural and/or biomarker measure apparent interim analysis , placebo treat subject offer TP ( FDA approve form , Forteo ) follow additional 24 week . If placebo subject choose participate crossover treatment yet complete 48 week visit , occur . These subject begin crossover portion 24 week treatment monitoring period receive TP pen ( FDA approve form , Forteo ) .</detailed_description>
	<mesh_term>Osteoarthritis</mesh_term>
	<mesh_term>Osteoarthritis , Knee</mesh_term>
	<mesh_term>Teriparatide</mesh_term>
	<criteria>1. male female 40 60 year old . 2. radiographic evidence KellgrenLawrence score ( KL score ) grade III OA affect knee 3. unilateral symptomatic knee OA 4. willingness forgo potential standard care treatment ( hyaluronic acid cortisol injection ) knee pain duration study 5. body Mass Index ≤40 6. normal screen vitamin D level ( ≥20 ≤100 mg/ml ) 7. normal screen serum calcium level ( 8.5 10.2 mg/dL ) 8. negative screen serum pregnancy test premenopausal woman 1. history primary hyperparathyroidism disease , hypercalcemia , persistently abnormal intake PTH level ( ≥10 ≤65 pg/ml ) 2. history musculoskeletal malignancy solid organ carcinoma 3. active renal disease define creatinine clearance &lt; 35 history kidney stone within past year 4. use anticonvulsant digoxin therapy 5. inflammatory disease ( bowel disease , spondylitis , lupus , fibromyalgia , psoriasis , rheumatoid arthritis , etc ) 6. current past treatment teriparatide 7. use immunosuppressant 8. severe claustrophobia , retain eye skull metal fragment , metal hardware around affected knee standard contraindication MRI ( cochlear implant , pacemaker ) 9. dementia , cognitive impairment factor refer provider feel would prevent ability obtain informed consent and/or follow study protocol 10. pregnancy intent become pregnant two half year follow enrollment 11. woman currently breastfeed 12 . Paget 's disease 13. osteoporosis diagnosis DXA medical history ( Tscore le equal 2.5 ) 14. reliance assistive walking device ( cane , walker , brace , etc . ) 15. participation concurrent clinical study involve investigational medication</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>